Spinal rigidity or scoliosis. Muscle weakness, hypertrophy or contractures (including calf and tongue hypertrophy). Note:
The mode of presentation and the pattern of muscle involvement. Whether there are any additional clinical features.
Interpretation of clinical patterns
The precise clinical pattern and course can help identify the specific LGMD cause. For example:
Neonatal hypotonia occurs in LGMD 1B.
Contractures are most common in LGMD 1B.
LGMD 2A -there is relative preservation of hip abductors and striking involvement of the posterior thigh muscles seen on MRI.
LGMD 2A and LGMD 2C-F -scapular winging is characteristic.
LGMD 2B -often have normal sporting ability until there is abrupt onset of symptoms.
LGMD 1C -may have rippling muscle disease, characterised by signs of increased muscle irritability, such as percussioninduced rapid contraction, percussion-induced muscle mounding and/or electrically silent muscle contractions (rippling muscle). [9] 
Specialist centres
In the UK, the Newcastle Muscle Centre is the national LGMD diagnostic and advisory service. The Dubowitz Neuromuscular Centre in London provides a diagnostic and advisory service for congenital muscular dystrophies and congenital myopathies. [11] Investigations [2, 8] Key investigations are:
Serum CK: This is often raised in LGMD, but can be normal in some types. Exclude non-muscle conditions first. The degree of CK elevation helps distinguish between different types.
Muscle imaging with CT or MRI -can show patterns of muscle involvement. [12] Muscle biopsy: This is most useful on muscle which is affected clinically but is not 'end-stage'. Analysed by immunohistochemistry and immunoblotting in an expert laboratory. All
LGMDs show dystrophic features with variations in fibre size, greater numbers of central nuclei and endomysial fibrosis.
Muscle biopsy immuno-analysis can suggest the diagnosis in many of the genetically defined types of LGMD.
DNA analysis: This is the 'gold standard' test, but its feasibility varies for different types of LGMD. It requires a specialist laboratory. For the rarer types of LGMD, this may only be available on a research basis.
In addition:
Myoglobinuria can occur in LGMD2I. [1] It has been reported in a patient with sarcoglycanopathy. [13] Cardiac and respiratory investigations are often appropriate, to monitor for complications (see 'Complications and their management', below).
It is possible to reach a precise diagnosis in around 75% of the LGMD patients.
Prenatal diagnosis
Genetic counselling should be offered. If the specific subtype of LGMD can be identified, prenatal diagnosis or carrier testing for other family members may be possible.
Differential diagnosis
Other muscular dystrophies. [8] Congenital myopathies. Dermatomyositis or polymyositis. Endocrine or metabolic myopathies, including Cushing's syndrome and thyrotoxicosis. Spinal muscular atrophy.
Management [2] There is no specific therapy for LGMD. [14] There is no specific therapy for LGMD. [14] Nondrug treatment Physiotherapy to prevent contractures, using passive stretching, exercise therapy, ± orthoses. [15] Exercise -the role of exercise in LGMD is controversial, but guidelines for other types of muscular dystrophy suggest gentle exercise within limits of comfort, and avoidance of prolonged immobility. Occupational therapy and aids such as a wheelchair, with careful attention to seating so as to minimise the development of scoliosis. Genetic counselling. Advice on benefits. Support groups (eg, Muscular Dystrophy Campaign). Monitoring for complications (see 'Complications and their Management', below).
Possible drug treatment
Corticosteroids have been used in some patients with LGMD 2C-F, giving improvement in some reported cases. [2, 16] A study involving two patients with dysferlin-deficient muscular dystrophy reported an improvement in muscle strength after treatment with rituximab. [17] Complications and their management [2, 8] Complications vary, depending on the specific LGMD and on individual variations in the clinical picture. Cardiac and respiratory surveillance are particularly important in LGMD 1B, LGMD 2C-F and LGMD 2I. Where the type of LGMD carries a high risk of cardiac or respiratory involvement, management should involve cardiac and respiratory physicians. This also applies in cases where the precise diagnosis is unknown.
Respiratory muscle weakness
This is most common in LGMD 2I and the sarcoglycanopathies. It leads to hypoventilation, which is often worse at night. Symptoms include frequent chest infections, morning headaches and daytime sleepiness. Anaesthesia [18] Rarely, a malignant hyperthermic reaction to general anaesthesia can occur. Caution is needed regarding possible cardiac complications. As in any muscle disease, succinylcholine administration could cause life-threatening hyperkalaemia and should be avoided.
Musculoskeletal complications
Contractures (eg, of the Achilles tendon) may require surgical release. Scoliosis -occurs mainly after wheelchair dependence. Careful attention to seating is important. Chronic pain can occur, and pain management should be part of care. [19] Prognosis This depends on the type of LGMD and whether there is cardiac or respiratory involvement. In general, all types of LGMD progress with time. However, this is highly variable between the different LGMD types and also between individuals with the same specific type or within a family. Also, the rate of progression is not necessarily linear. [2] Research Possible future treatments include:
Antisense-mediated exon skipping -this is a promising therapeutic approach for Duchenne muscular dystrophy. It may be applicable to conditions caused by mutations in the dysferlin gene -eg, LGMD 2B and Miyoshi myopathy. [21] Gene therapy is a potential form of treatment. [22] Appendix -summary of limb-girdle muscular dystrophy types and their clinical features [1, 7, 8] 
Types of LGMD and their clinical features

Type of LGMD (and the protein involved, if known)
Usual age of onset (approximate)
Notable clinical features (in addition to proximal muscle weakness)
LGMD LGMD 1B (lamin A/C)
Childhood
May have neonatal hypotonia. There is usually slow progression. Cardiac involvement, including arrhythmias, is common and may be the only manifestation of the condition; may require an implantable defibrillator. May have respiratory involvement. May have distal muscle weakness and contractures.
LGMD 1C (caveolin 3)
Childhoodadult
Rippling muscle disease (see 'Presentation' section). Cramps and myalgia after exercise are common. There is usually slow progression. Usually there is no cardiac or respiratory involvement. May have muscle hypertrophy and distal muscle weakness. Extraocular muscle involvement has been reported in one case. [23] LGMD 1D-F Adulthood This is very rare. Proximal weakness with cardiac conduction defects and, later, dilated cardiomyopathy. May have normal CK.
LGMD 2A (calpain 3)
Childhood (8) (9) (10) (11) (12) (13) (14) (15) There is mainly proximal muscle weakness. There is slow progression. Muscle atrophy is prominent (notable sparing of the hip abductors).
Contractures are common. Usually there is no cardiac or respiratory involvement. One case is reported as presenting with foot drop -aged 41. [24] LGMD 2B (dysferlin) also known as Miyoshi myopathy
Late teens, early 20s
May have distal myopathy (Miyoshi myopathy). Markedly elevated CKs. Usually there is no cardiac or respiratory involvement. Many patients have good muscle strength, leading to good performance at sports or in physically demanding jobs, before onset of symptoms.
[25] May have calf muscle pain and swelling.
LGMD 2C-F (sarcoglycan proteins)
Childhood
There is a variable rate of progression.
Contractures may develop. Cardiac involvement and respiratory involvement are common.
LGMD 2G (telethonin) Childhood This is rare outside Brazil. There is distal leg weakness. May have cardiac involvement; there is no respiratory involvement. May have normal CK.
LGMD 2H (TRIM 32) Young adult This is rare outside Canada. May have mild facial weakness. May have cardiac involvement; there is no respiratory involvement. May have normal CK.
LGMD LGMD 2L (fukutin)
There is deterioration of weakness with viral infections. May have cardiac and respiratory involvement.
LGMD 2M Age 10-50 There is asymmetric wasting of leg muscle (quadriceps femoris).
LGMD 2N (POMT2)
Childhood (?) This has been described recently.
Types of LGMD and their clinical features [1, 7, 8] There is a wide spectrum of symptoms -from a milder form of LGMD to severe muscle weakness and wasting. May have learning difficulties. May have eye problems.
Types of LGMD and their clinical features [1, 7, 8] Further 
